Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Elastrin Therapeutics logo — Using drug-loaded nanoparticles for the effective treatment...

Elastrin Therapeutics

Using drug-loaded nanoparticles for the effective treatment of life-threatening diseases

Founded 2017 United Kingdom Oxford, United Kingdom 8 employees Venture round Total: $20.85M Biopharma, Biotechnology +1

General Information

Company Name Elastrin Therapeutics
Founded Year 2017
Location United Kingdom Oxford, United Kingdom
Employees 8
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Elastrin Therapeutics. To contact Elastrin Therapeutics, visit elastrin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Elastrin Therapeutics compare?

A PDF of Elastrin Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Elastrin Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Elastrin Therapeutics

Elastrin Therapeutics is a UK and US-based biotech company founded in 2017 with the slogan "Using drug-loaded nanoparticles for the effective treatment of life-threatening diseases." The company focuses on developing novel therapies to reverse cardiovascular disease by utilizing its proprietary platform that targets and restores degraded elastin, while removing harmful calcification that stiffens arteries. The underlying technology was developed by Dr. Naren Vyavahare and Dr. Charles Rice over the last 20 years at Clemson University. In its latest funding round on 03 November 2023, Elastrin Therapeutics secured a $4.75M Venture Round investment. The company operates in the Biopharma and Biotechnology industries and is headquartered in the United Kingdom. With its innovative approach to tackling cardiovascular diseases, Elastrin Therapeutics presents an intriguing investment opportunity in the biotech sector due to its promising technology and potential to make a significant impact on healthcare.

Business keywords: Biotech, Cardiovascular Diseases, Drug Discovery, Nanoparticles, Therapeutics, Elastin, Artery Health, Particle Design, Calcification Removal, Targeted Drug Delivery, Medical Research, Innovation, Life Sciences

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $4.75M -
03 Nov 2023
Seed Round $10.00M 3
Kizoo Technology Capital
Kizoo Technology Capital, SC Launch, Inc. +1
07 Apr 2022
Venture Round $3.60M -
25 Mar 2022
Seed Round $2.50M 1
Kizoo Technology Capital
Kizoo Technology Capital
04 Mar 2021

Elastrin Therapeutics Alternatives & Competitors

View All Alternatives
Elastrin Therapeutics vs
Certa Therapeutics
Certa Therapeutics

Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases

Grant
10 employees
Biotechnology, Health and Wellness
Elastrin Therapeutics vs
Nanna Therapeutics
Nanna Therapeutics United Kingdom

Disease-modifying Medicines

Grant
20 employees
AI, Biotechnology
Elastrin Therapeutics vs
Bound Therapeutics
Bound Therapeutics United States

Safe and effective next generation RNA therapeutics

3 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Elastrin Therapeutics

Using drug-loaded nanoparticles for the effective treatment of life-threatening diseases
Elastrin Therapeutics was founded in 2017.
Elastrin Therapeutics is headquartered in Oxford, United Kingdom.
Elastrin Therapeutics operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on Biotech, Cardiovascular Diseases, Drug Discovery and Nanoparticles.
Elastrin Therapeutics has approximately 8 employees.
Elastrin Therapeutics has completed 4 funding rounds, raising a total of $20.85M. The latest funding stage is Venture round.
Top alternatives and competitors to Elastrin Therapeutics include Certa Therapeutics, Nanna Therapeutics, Bound Therapeutics, iN Therapeutics, BioCryst Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elastrin Therapeutics and Certa Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Elastrin Therapeutics, https://bouncewatch.com/company/elastrin-therapeutics, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes